Alembic Pharmaceuticals Limited has executed a Shareholders' Agreement to invest in a newly incorporated Canadian Corporation as part of its plans to expand its pharmaceutical presence in the Canadian market. According to reports from CNBC TV18, the company will hold a 45% equity stake in the Canadian entity following the investment. The agreement was signed on June 6, 2026, with Difgen Holdings LLC and Mr Sukhad Juneja for investing in shares of 17989377 Canada Inc., the Canadian Corporation. The disclosure was made to stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
As per the agreement, Alembic Pharmaceuticals will hold a 45% stake in the Canadian Corporation, while Difgen Holdings LLC will also hold a 45% stake. The remaining 10% stake will be held by others. Following the investment, the Canadian Corporation will become an associate company of Alembic Pharmaceuticals. The Board of Directors of the Canadian Corporation will comprise nominee directors of the shareholders along with an independent director, with the agreement including customary shareholder rights, including participation in key decision-making matters. The filing confirmed that the parties to the joint venture are not related to the promoter, promoter group, or group companies of Alembic Pharmaceuticals in any manner.
The investment is aimed at establishing a platform for the development, commercialisation, distribution and marketing of pharmaceutical products focused on the Canadian market. According to CNBC TV18, this strategic move represents Alembic's commitment to expanding its pharmaceutical operations beyond its current markets into the Canadian healthcare sector.
Alembic Pharmaceuticals stated that the transaction does not fall under related party transactions and there is no potential conflict of interest arising from the agreement. As reported by CNBC TV18, shares of Alembic Pharmaceuticals Limited closed at ₹742.75 on the NSE, up ₹5.20 or 0.71% following the announcement of this strategic investment. The specific details regarding the issue price and class of shares were noted as not applicable in the regulatory filing.
